Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Go back to Resources

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

Go back to Resources

Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Patient registries for substance use disorders.

Go back to Resources

Patient registries for substance use disorders.

Authors:

Secondary:

Volume:

Pagination:

PMID:

DOI:

Abstract:

Go back to Resources

Myelodysplastic syndromes in the United States: an update for clinicians.

Go back to Resources

Myelodysplastic syndromes in the United States: an update for clinicians.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Go back to Resources

Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Parent-based sleep education for children with autism spectrum disorders.

Go back to Resources

Parent-based sleep education for children with autism spectrum disorders.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Impact of patient use of an online patient portal on diabetes outcomes.

Go back to Resources

Impact of patient use of an online patient portal on diabetes outcomes.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Go back to Resources

Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Chimpanzee Adenovirus Vector Ebola Vaccine.

Go back to Resources

Chimpanzee Adenovirus Vector Ebola Vaccine.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.

Go back to Resources

Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 67
  • Page 68
  • Page 69
  • Page 70
  • Current page 71
  • Page 72
  • Page 73
  • Page 74
  • Page 75
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions